For this experiment the HDAC inhibitor Vorinostat, which is already approved for CTCL treatment (Mann et al., 2007), and the DOT1L inhibitor Pinometostat, which is in clinical trials for MLL-rearranged leukemia (Stein et al., 2018), were chosen. Here, DOT1L is linked to primary cutaneous T-cell non-Hodgkin lymphoma.